MassBio is a non-profit organization that represents and provides support for the life sciences supercluster in Massachusetts. MassBio is committed to growing the industry, adding value to healthcare, and improving the lives of patients through an unmatched network of companies. The organization’s Annual Meeting, which was held in none other than Cambridge, MA on March 21 and 22 was every bit as impressive as the mission that MassBio has undertaken.
Two members of ProPharma Group’s Product Management group were in attendance at this meeting and the breadth of knowledge and expertise left them in awe. Attendance at the meeting was a virtual who’s who of the biotech industry, and included many of the people who started biotech in the US. These “rock stars” told stories of how products we take for granted today were developed with as much luck as science.
Though there were many impressive discussions, panels, and topics, a few key points were of great interest;
The meeting concluded with a key note address from the Deputy Commissioner for Policy, Planning, Legislation, and Analysis of the FDA. She outlined what steps the FDA has taken since 2016 to increase reviews and approvals of various filings as well as what the next two years look like for the FDA, as delineated by the current administration. Some key numbers included generic product approvals, which were up by more than 200 approvals over the previous highest year, including five biosimilars.
The threat of a Boston Nor’easter could not stop the industry leaders from attending the event to discuss the most critical challenges facing the Massachusetts biopharma industry. The Annual Meeting covered innovative breakthroughs, startups, new business ventures, and many groundbreaking advancements in the industry.
November 15, 2018
Increasing safe and effective patient treatment opportunities for the future is one of the driving forces behind ProPharma Group’s business. It’s also the driving force behind why many individuals...
March 20, 2019
Operating a business under a Consent Decree is extremely difficult; there is no area of the business that goes unaffected. In addition to fines that could reach $500 million, a three to five-year...
October 28, 2015
In the space of a few years, Medical Information outsourcing has moved from being a last resort to become a core part of the service delivery strategy for most pharmaceutical companies. The speed of...